BETA
This is a BETA experience. You may opt-out by clicking here

More From Forbes

Edit Story

Agree To Purchase Biogen Idec At $230, Earn 8.3% Using Options

Following
This article is more than 9 years old.

Investors eyeing a purchase of Biogen Idec Inc (NASD: BIIB) stock, but tentative about paying the going market price of $320.00/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2017 put at the $230 strike, which has a bid at the time of this writing of $19.10. Collecting that bid as the premium represents a 8.3% return against the $230 commitment, or a 3.7% annualized rate of return (at Stock Options Channel we call this the YieldBoost).

Click here to find out the Top YieldBoost Puts of the Nasdaq 100 »

Selling a put does not give an investor access to BIIB's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $230 strike if doing so produced a better outcome than selling at the going market price. (Do options carry counterparty risk? This and six other common options myths debunked). So unless Biogen Idec Inc sees its shares decline 28.1% and the contract is exercised (resulting in a cost basis of $210.90 per share before broker commissions, subtracting the $19.10 from $230), the only upside to the put seller is from collecting that premium for the 3.7% annualized rate of return.

Below is a chart showing the trailing twelve month trading history for Biogen Idec Inc, and highlighting in green where the $230 strike is located relative to that history:

The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2017 put at the $230 strike for the 3.7% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for Biogen Idec Inc (considering the last 251 trading day closing values as well as today's price of $320.00) to be 37%. For other put options contract ideas at the various different available expirations, visit the BIIB Stock Options page of StockOptionsChannel.com.

In mid-afternoon trading on Monday, the put volume among S&P 500 components was 553,837 contracts, with call volume at 553,837, for a put:call ratio of 0.75 so far for the day, which is above normal compared to the long-term median put:call ratio of .65. In other words, if we look at the number of call buyers and then use the long-term median to project the number of put buyers we'd expect to see, we're actually seeing more put buyers than expected out there in options trading so far today.

Find out which 15 call and put options traders are talking about today.


Special Offer: Join the income investing conversation on ValueForum.com with a special Seven Days for Seven Dollars invitation from Forbes.